

# Cobalamin-responsive disorders in the ambulatory care setting: unreliability of cobalamin, methylmalonic acid, and homocysteine testing

Lawrence R. Solomon

**Early recognition of cobalamin (Cbl)-responsive disorders in the ambulatory care setting is essential to prevent irreversible neurologic deficits. However, diagnostic algorithms using Cbl, methylmalonic acid (MMA), and homocysteine (HCys) measurements reflect studies in academic centers, and their negative predictive values have not been established. Thus, records of 456 ambulatory patients evaluated for Cbl deficiency at a staff model HMO were reviewed. Pretherapy**

**Cbl, MMA, and HCys values in individual patients varied by 23%, 23%, and 17%, respectively, over 2 to 6 weeks. Hematologic or neurologic responses to pharmacologic doses of Cbl occurred in 37 of the 95 evaluable patients. In these patients, pretherapy Cbl, MMA, and HCys values were normal in 54%, 23%, and 50%, respectively. If therapy had been restricted to symptomatic patients with both low or intermediate Cbl levels and increased metabolite values, 63% of responders would**

**not have been treated. Twenty-five patients did not respond to treatment, including 5 of 11 patients (45%) with low Cbl, 22 of 49 patients (45%) with high MMA, and 13 of 30 patients (43%) with high HCys values. It is concluded that Cbl, MMA, and HCys levels fluctuate with time and neither predict nor preclude the presence of Cbl-responsive hematologic or neurologic disorders. (Blood. 2005;105:978-985)**

© 2005 by The American Society of Hematology

## Introduction

While cobalamin (Cbl) deficiency classically causes macrocytic anemia, anemia can occur without macrocytosis, and both neurologic and cognitive dysfunction often develop in the absence of hematologic changes.<sup>1-5</sup> Symptoms consistent with Cbl deficiency, including paresthesias, unsteady gait, fatigue, and impaired memory, are commonly encountered in the ambulatory care setting, and early recognition of Cbl deficiency is important to prevent progressive, irreversible neurologic and cognitive impairment.<sup>6,7</sup>

Although treatment with Cbl is often initiated after the finding of a low serum Cbl level, many patients with low Cbl levels are not Cbl deficient.<sup>8,9</sup> As a result, measurements of the Cbl-dependent metabolites, methylmalonic acid (MMA) and homocysteine (HCys), have recently been used to confirm the presence of Cbl deficiency. Retrospective studies of patients at academic medical centers with low serum Cbl levels and clinically overt Cbl deficiency found MMA and/or HCys levels more than 3 standard deviations (SD) above the normal mean in almost all patients.<sup>8,10-12</sup> Thus, algorithms for the diagnosis of Cbl deficiency were developed that suggest initial measurement of serum Cbl followed by determination of MMA and HCys when Cbl levels are intermediate or when suspicion of clinically significant Cbl deficiency is high.<sup>8,13-20</sup> However, because little attention has been given to the study of patients with clinical findings consistent with Cbl deficiency but normal vitamin and metabolite levels, the negative predictive value of these tests is uncertain. Indeed, Cbl levels are normal in some patients with overt deficiency,<sup>11</sup> and currently available Cbl assay kits may not be reliable.<sup>21,22</sup> Moreover, because studies from academic centers usually employed special diagnostic or research

laboratory facilities, their findings may not be representative of those obtainable in other ambulatory care settings.

Thus, a retrospective review of patients evaluated for Cbl deficiency during a 10-year period at a staff model HMO utilizing a national commercial laboratory was performed. Initially, only patients with low serum Cbl levels or elevated metabolite levels received therapeutic trials of Cbl. However, in the seventh year of the study period, one patient with total absence of vibratory sensation in the iliac crest, knees, and ankles had complete recovery following 2 months of Cbl therapy despite normal Cbl, MMA, and HCys levels. Thereafter, therapy was offered to all patients with hematologic or neurologic abnormalities consistent with Cbl deficiency regardless of the results of screening studies.

## Patients, materials, and methods

### Laboratory methods

Serum Cbl was measured by the ADVIA Centaur chemiluminescence assay (Bayer Diagnostics, Tarrytown, NY). Normal Cbl values were 200 to 1100 pg/mL, but higher reference ranges have been suggested,<sup>11,13,16,17,20,23,24</sup> and the statement "patients with values less than 300 pg/mL may experience unexplained neuropsychiatric or hematologic abnormalities due to occult B12 deficiency" was appended to test reports during the last 4 years of the study. Thus, Cbl levels were defined as low (below 201 pg/mL), intermediate (201 to 300 pg/mL), or normal (above 300 pg/mL).

Serum MMA was measured by gas chromatography/mass spectroscopy with a reference range of 90 to 250 nmol/L during the first 4 years of the study and 90 to 279 nmol/L during the last 6 years. For a brief time, normal

From the Department of Medicine, Yale University Health Services, New Haven, CT; and Section of Hematology, Department of Medicine, Yale University School of Medicine, New Haven, CT.

Submitted April 29, 2004; accepted September 23, 2004. Prepublished online as *Blood* First Edition Paper, October 5, 2004; DOI 10.1182/blood-2004-04-1641.

An Inside *Blood* analysis of this article appears in the front of this issue.

**Reprints:** Lawrence R. Solomon, Department of Medicine, Yale University Health Services, 17 Hillhouse Ave, PO Box 208237, New Haven, CT 06520-8237; e-mail: lawrence.solomon@yale.edu.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.

© 2005 by The American Society of Hematology

MMA values were reported as below 400 nmol/L. Thus, MMA levels below 251 nmol/L and those reported as below 400 nmol/L were considered to be normal, while values of 251 to 376 nmol/L were considered to be moderately increased (ie, 2 to 3 SD above the normal mean) and values above 376 nmol/L were considered to be elevated (ie, more than 3 SD above the normal mean).

Plasma HCys was measured by the Abbott AxSYM fluorescent polarization immunoassay (HPA; Abbott Park, IL). Plasma was removed by centrifugation and frozen immediately after the sample was obtained. The reference range varied during the study period but was 5.4 to 12.1 μmol/L at the time most evaluations were performed. Thus, HCys levels below 12.2 μmol/L were considered to be normal, values of 12.2 to 13.6 μmol/L were considered to be moderately increased (ie, 2 to 3 SD above the normal mean), and values above 13.6 μmol/mL were considered to be elevated (ie, more than 3 SD above the normal mean).

**Patients**

A retrospective review of the medical records of 456 patients evaluated on 510 occasions by the author for Cbl deficiency between August 1, 1993, and September 30, 2003, was conducted. A total of 152 asymptomatic hematologically healthy patients were screened for Cbl deficiency because of the presence of conditions associated with Cbl depletion. Of the remaining 304 patients with clinical or laboratory abnormalities, 49 patients were excluded from this review because they were evaluated for cognitive dysfunction or nonspecific systemic complaints that were not objectively measured.

The remaining 255 patients had hematologic and/or neurologic findings consistent with Cbl deficiency. Cbl therapy was not offered to 127 of these patients because of the presence of one or more of the following: normal serum Cbl or MMA levels in 125 patients (98%); loss to follow-up in 26 patients (20%); resolution of signs, symptoms, or laboratory abnormalities prior to Cbl therapy in 12 patients (9%); and/or the presence of other causes for the clinical findings in 60 patients (47%). Of the 128 patients who received therapeutic trials of Cbl, 33 were considered unevaluable because of inadequate follow-up or noncompliance in 16 patients (50%); response associated with the use of another therapeutic modality in addition to Cbl in 8 patients (25%); and/or the presence of another disorder that could explain the clinical picture in 10 patients (30%). The remaining 95 patients received at least 3 months of Cbl therapy and were evaluable for hematologic and/or neurologic responses to treatment.

**Cbl treatment**

Patients with suspected deficiency were treated with cyanocobalamin 2 mg per day orally or 1 mg intramuscularly 3 times a week for 2 weeks, weekly for 8 weeks, and monthly thereafter. All patients were reevaluated within 3 months of beginning Cbl therapy.

**Criteria for Cbl-responsive clinical disorders**

Criteria for clinically significant responses to Cbl therapy were the same as those used in previous reports except that peripheral smears were not systematically reviewed for the presence of macroovalocytes or hypersegmented neutrophils.<sup>1,2,8,11,12</sup> Thirty-seven patients were considered to have a definite response to therapy (responders). Hematologic improvement in these patients during Cbl therapy was considered to be significant if mean corpuscular volume (MCV) values above 98 fL decreased by at least 5 fL or if hematocrit values increased by at least 0.05 hematocrit points from values below 0.36 in women and below 0.39 in men. Neurologic improvement in these patients during Cbl therapy was considered to be significant if paresthesias completely resolved, observed ataxic gait became normal, and/or vibratory sensation that was completely absent at least in the ankles prior to therapy became easily detectable within 6 months of treatment. In contrast, 25 patients with macrocytosis, anemia, or neurologic deficits who had no other apparent causes for these abnormalities and who had no improvement after at least 3 months of Cbl therapy were considered nonresponders.

An additional 33 patients were considered possible responders because of less striking improvements in clinical findings, including a decrease in MCV of 3 to 4 fL; an increase in hematocrit of 0.03 to 0.04 hematocrit points; and partial improvement in paresthesias, ataxic gait, or vibratory sensation. Laboratory findings in these patients are shown in "Appendix 3."

**Statistical methods**

Average differences between repeat measurements of Cbl, MMA, and HCys were expressed as the mean ± 1 standard deviation (SD). Statistical significance was assessed by the 2-tailed Student *t* test.

**Results**

**Intraindividual variation in serum Cbl and metabolites**

Repeat measurements of Cbl, MMA, and HCys prior to therapy were obtained within 2 to 6 weeks to confirm abnormal values or when the suspicion of Cbl deficiency was high despite initial normal test results. Average intraindividual variations in all 3 parameters were considerable, and a wide range of values was noted even when outliers with marked differences in the 2 test results obtained were omitted from analysis (Table 1). The variations in MMA and HCys were significantly greater in patients with at least one elevated value than in those in whom both values were within the normal reference range (*P* < .001 and *P* = .011, respectively). Overall, differences in Cbl values were above 100 pg/mL in 21% of patients, while differences in MMA levels above 100 nmol/L occurred in 24% of patients and differences in HCys levels above 2.5 μmol/L were present in 22% of patients (data not shown).

Moreover, test variability significantly affected whether or not a patient might be considered to be Cbl deficient. Thus, normal MMA and HCys values were associated with higher metabolite levels in 37% and 26% of events, respectively, while 49% of patients with Cbl levels above 300 pg/mL also had values in the low or intermediate range (Table 2).

**Table 1. Intraindividual variation in serum Cbl and metabolites**

Measurement	No.	Intraindividual variation (median)*	Percent variation (median)†‡
<b>Cbl, pg/mL</b>			
All patients	304	66 ± 63 (47)	23 ± 21 (16)
Range	—	0-291	0-119
<b>High MMA‡</b>			
Less than 251 nmol/L	32	24 ± 30 (14)	18 ± 29 (9)
Greater than 250 nmol/L	99	75 ± 65 (60)	24 ± 24 (16)
Greater than 376 nmol/L	55	104 ± 72 (96)	26 ± 21 (21)
All patients	131	63 ± 53 (47)	23 ± 21 (16)
Range	—	0-280	0-146
<b>High HCys§</b>			
Less than 12.2 μmol/L	42	1.3 ± 1.0 (1.0)	17 ± 14 (15)
Greater than 12.1 μmol/L	64	2.2 ± 2.1 (1.6)	16 ± 18 (11)
Greater than 13.6 μmol/L	51	2.5 ± 2.3 (1.8)	18 ± 20 (12)
All patients	106	1.8 ± 1.8 (1.5)	17 ± 17 (14)
Range	—	0-11.0	0-121

\*Values are means ± 1 SD for the differences between 2 consecutive values in each patient.

†Percent variation was calculated as the difference between 2 consecutive values divided by the lowest value obtained and then multiplied by 100.

‡Excludes 5 outliers with high MMA values above 560 nmol/L and changes of MMA above 340 nmol/L on repeat determinations.

§Excludes 2 outliers with high HCys values of 99.3 and 60.7 and changes of 36.3 and 20.3, respectively, on repeat determinations.

**Table 2. Effects of pretherapy variations in Cbl, MMA, and HCys on patient classification**

Measurement	No. with 1 normal pretherapy value*	Second pretherapy value, no. (%)	
		Normal	Abnormal
Cbl	181	93 (51)	88† (49)
MMA	51	32 (63)	19‡ (37)
HCys	57	42 (74)	15§ (26)

Normal values were defined as follows: Cbl, greater than 300 pg/mL; MMA, less than 251 nmol/L; HCys, less than 12.2  $\mu$ mol/L.

\*Includes all patients tested on 2 occasions within 6 weeks. Either the initial or repeat test result was within the normal range.

†Includes 8 patients with Cbl values less than 201 pg/mL (4%).

‡Includes 3 patients with MMA values greater than 376 nmol/L (6%).

§Includes 8 patients with HCys values greater than 13.6  $\mu$ mol/L (14%).

### Patients with clinical responses to Cbl therapy

Clinical responses to Cbl therapy occurred in 37 patients. Hematologic responses occurred in 8 patients, including 6 patients with a fall in MCV, 1 patient with a fall in MCV associated with an increase in hematocrit, and 1 patient with an increase in hematocrit alone. In all 7 patients with macrocytosis, MCV values decreased to values below 98 fL. Neurologic responses occurred in 30 patients, including 21 patients with resolution of paresthesias, 13 patients with improvement in vibratory sensation, and 7 patients with correction of ataxic gait. Ten patients had 2 or more neurologic abnormalities that resolved with Cbl therapy. One patient had improvement of both hematologic and neurologic abnormalities. Cbl was administered intramuscularly to 30 patients (81%), including 24 of the 30 patients (80%) with neurologic responses. Other medical problems that may be associated with hematologic or neurologic abnormalities were present in 15 of these patients ("Appendix 1"). However, in every case, the response to Cbl therapy occurred without concurrent changes in the severity of these disorders and in the absence of other therapeutic interventions.

Serum Cbl was measured in all 37 patients, and a second pretherapy determination was obtained in 24 of them (65%). MMA and HCys were measured in 35 patients and 34 patients, with second pretherapy determinations obtained in 22 patients (63%) and 17 patients (50%), respectively. To maximize the sensitivity of these tests, the lowest pretherapy Cbl levels and the highest metabolite values obtained were used for analysis.

As shown in Table 3, serum Cbl values were above 200 pg/mL in 84% of responders, including 62% of patients with hematologic responses and 90% of patients with neurologic responses. Only 1 patient had a serum Cbl level below 150 pg/mL. In fact, 20 patients had serum Cbl levels above 300 pg/mL (54%), including 15 patients with Cbl levels above 400 pg/mL (41%).

Pretherapy MMA values were considered to be normal using reference laboratory criteria at the time of evaluation in 8 of the 35 responders studied (23%), including 2 of 7 patients with hematologic responses (29%) and 6 of 29 patients with neurologic responses (21%) (Table 3). Moreover, MMA values were above 376 nmol/L in only 13 responders (37%). Only 1 of the 22 patients with normal or moderately increased MMA values was receiving antibiotics at the time of evaluation while the remaining 21 patients had not received antibiotics for at least 6 weeks prior to testing and 19 had not received antibiotics for at least 3 months. Similarly, HCys values were normal in 17 of the 34 responders studied (50%) (Table 3).

Overall, both metabolites were normal in 7 of the 33 evaluable patients (21%). If algorithms were used to limit Cbl therapy to

**Table 3. Serum Cbl and metabolite levels in clinical responders**

Screening parameters	Hematologic responders, no. (%)	Neurologic responders, no. (%)	All responders, no. (%)
<b>Cbl</b>			
Less than 201 pg/mL	3 (38)	3 (10)	6 (16)
201 pg/mL to 300 pg/mL	5* (62)	7* (23)	11* (30)
Greater than 300 pg/mL	0 (0)	20 (67)	20 (54)
<b>MMA</b>			
Less than 251 nmol/L	2† (29)	6 (21)	8† (23)
251 nmol/L to 376 nmol/L	0 (0)	14 (48)	14 (40)
Greater than 376 nmol/L	5* (71)	9* (31)	13* (37)
<b>HCys</b>			
Less than 12.2 $\mu$ mol/L	2 (40)	14 (48)	17 (50)
12.2 $\mu$ mol/L to 13.6 $\mu$ mol/L	0 (0)	2 (7)	2 (6)
Greater than 13.6 $\mu$ mol/L	3* (60)	13* (45)	15* (44)

Pretherapy Cbl was measured in all 37 responders. Pretherapy MMA was measured in 35 responders, including 7 of 8 hematologic responders and 29 of 30 neurologic responders. Pretherapy HCys was measured in 34 responders, including 5 of 8 hematologic responders and 29 of 30 neurologic responders.


\*Includes the one patient who had both a hematologic and neurologic response to Cbl therapy.

†Includes 2 patients with values reported as less than 400  $\mu$ mol/L.

patients with *both* Cbl levels below 301 pg/mL and MMA levels above 250 nmol/L, 22 of the 35 evaluable Cbl-responsive patients would not have received a therapeutic trial (63%) (Figure 1). Even extending criteria for treatment to include patients with Cbl levels below 401 pg/mL and MMA levels above 250 nmol/L would have missed 17 patients with clinical responses to Cbl therapy (49%) (data not shown). An increased HCys value identified only one additional responder with normal Cbl and MMA levels.

### Predictors of clinical response to Cbl therapy

An additional 25 patients received Cbl therapy without significant improvement, including 12 patients with MCV values above 98 fL (4 of these patients also had anemia with hematocrit values of 0.34 to 0.38); 12 patients with otherwise unexplained normocytic anemia; and 5 patients with neurologic abnormalities, including



**Figure 1. Pattern of Cbl, MMA, and HCys values in patients with clinical responses to Cbl therapy.** Serum, Cbl, and MMA were measured on at least one occasion in 35 of the 37 patients with clinical responses to Cbl therapy, and serum HCys was also measured in 34 of these patients. The values shown represent the lowest pretherapy serum Cbl value and the highest pretherapy serum metabolite values obtained for each patient. Serum Cbl levels were defined as low (<201 pg/mL), intermediate (201 to 300 pg/mL), or normal (above 300 pg/mL). Normal metabolite levels were <251 nmol/L for MMA and <12.2  $\mu$ mol/L for HCys. \*MMA values in both of these cases were reported as below 400 nmol/L. Cbl indicates cobalamin; MMA, methylmalonic acid; HCys, homocysteine.

**Table 4. Predictors of response to Cbl therapy**

Parameter	Total no.	Responders, no. (%)	Nonresponders, no. (%)
No. treated	62	37 (60)	25 (40)
<b>Low serum Cbl</b>			
Less than 201 pg/mL	11	6 (55)	5 (45)
201 pg/mL to 300 pg/mL	20	11 (55)	9 (45)
Greater than 300 pg/mL	31	20 (65)	11 (35)
<b>High serum MMA</b>			
Greater than 376 nmol/L	28	13 (46)	15* (54)
251 nmol/L to 376 nmol/L	21	14† (67)	7 (33)
Less than 251 nmol/L	11	8‡ (73)	3 (27)
<b>High serum HCys</b>			
Greater than 13.6 $\mu$ mol/L	24	15†§ (63)	9 (37)
12.2 $\mu$ mol/L to 13.6 $\mu$ mol/L	6	2 (33)	4 (67)
Less than 12.2 $\mu$ mol/L	25	17 (50)	8 (32)

MMA was not measured before therapy in 2 responders while HCys was not measured before therapy in 3 responders and 4 nonresponders. Serum or red cell folate levels were normal in the 9 patients with Cbl levels less than 201 pg/mL tested and in all 30 patients with HCys values greater than 12.1  $\mu$ mol/L.

\*One patient with normal renal function did not have a fall in MMA after Cbl therapy.

†One patient with mild renal failure did not have a fall in either MMA or HCys after Cbl therapy.

‡Includes 2 patients with pretherapy MMA reported as less than 400 nmol/L.

§One patient with excessive alcohol consumption did not have a fall in HCys after Cbl therapy.

paresthesias in 3 patients, paresthesias associated with impaired vibration sensation in 1 patient, and ataxic gait alone in 1 patient. Four patients had both hematologic and neurologic abnormalities. All patients received at least 3 months of Cbl therapy, and 20 patients were treated for at least 6 months, including 4 of the 5 patients with neuropathy. Cbl was administered intramuscularly in 16 of these patients (65%), including all 5 patients with neuropathy.

As shown in Table 4, 14 of the 31 patients with serum Cbl levels below 301 pg/mL (45%) and 5 of 11 patients with serum Cbl levels below 201 pg/mL (45%) did not improve with Cbl therapy. Similarly, 22 of 49 patients (45%) with MMA values above 250 nmol/L and 13 of 30 patients (43%) with HCys values above 12.1  $\mu$ mol/L were nonresponders (Table 4). The same pattern was seen in patients with more marked increases in metabolite levels. Thus, 54% of patients with MMA values above 376 nmol/L were nonresponders despite the fact that Cbl therapy led to a fall in MMA of at least 200 nmol/L within 1 month in 12 of the 13 nonresponders (data not shown) and in 11 of the 12 responders studied ("Appendix 2"). Similarly, 37% of patients with HCys values above 13.6  $\mu$ mol/L were nonresponders.

Moreover, within each group, the proportion of patients with abnormal test results was similar. Thus, low or intermediate Cbl levels were present in 46% of responders and 56% of nonresponders, increased MMA values were present in 73% of responders and 88% of nonresponders, and increased HCys values were present in 50% of responders and 62% of nonresponders.

## Discussion

Recent approaches to Cbl deficiency reflect the recognition that neither macrocytosis nor anemia is consistently present in patients with neurologic or cognitive dysfunction.<sup>1-5</sup> In addition, assays for serum MMA and HCys have become available and algorithms have been developed for the use of these tests in patients with an appropriate clinical picture.<sup>9-11,13-20,25</sup> In general, initial measurement of serum Cbl has been suggested followed by determination

of MMA and HCys when Cbl levels are intermediate or when suspicion of clinically significant Cbl deficiency is high.

Cost-effective clinical decision making often leads to reliance on a single test result particularly when more expensive tests such as metabolite assays are involved. Thus, it is important to appreciate how greatly test results may fluctuate over time in individual subjects. As shown in Table 1, serum Cbl levels varied significantly in individual patients. In fact, the large variations observed using the current chemiluminescence assay were similar to those previously reported more than 40 years ago using early microbiologic methods.<sup>26,27</sup> Large intraindividual variations in MMA and HCys were also observed in the present study (Table 1). While the changes observed in patients with normal metabolite levels were similar to those previously reported in healthy subjects,<sup>28-34</sup> fluctuations were even greater in patients with at least one elevated metabolite value (Table 1). Most significantly, many patients with normal Cbl or metabolite values also had abnormal test results when a second pretherapy measurement was obtained (Table 2). Thus, short-term fluctuations of Cbl, MMA, and HCys may obscure the presence of Cbl deficiency. The variation in MMA and HCys levels may also lead to erroneous conclusions regarding responses of these metabolites to Cbl or folate therapy.

Previous studies of serum metabolites in patients with clinical responses to Cbl therapy found MMA and/or HCys levels more than 3 SD above the normal mean in almost all patients.<sup>1,8,10-12</sup> However, patients in these studies were preselected for the presence of low serum Cbl levels, and survey studies of ambulatory populations have found elevated MMA levels in many subjects with serum Cbl levels well within the normal range.<sup>16,23,24,35-38</sup> Only one study contrasted the serum metabolite levels in 86 patients with clinical responses to Cbl therapy with those in 59 patients who did not improve with Cbl therapy.<sup>9</sup> While 94% of responders had increases of one or both metabolites at least 3 SD above the normal mean, it was also notable that 12 of 61 patients (21%) with normal or less striking increases in MMA were responders, as were 13 of 51 patients (25%) with normal or less striking increases in HCys. All of the subjects in this study had serum Cbl levels below 200 pg/mL. Thus, reports of Cbl therapy in patients with either intermediate or high Cbl levels and/or normal metabolite levels are limited, and the negative predictive value of normal test results remains to be established.

Strikingly, one patient in the present series had total absence of vibratory sensation in the iliac crest, knees, and ankles, which resolved completely after 2 months of Cbl therapy despite normal Cbl and metabolite levels. Thus, in the present study, patients with a clinical picture consistent with Cbl deficiency were evaluated with metabolite measurements and often given Cbl therapy regardless of their Cbl, MMA, and HCys values. Indeed, only 16% of patients with clinical responses to Cbl therapy had "low" serum Cbl levels, and values were above 300 pg/mL in 54% of cases (Table 3). Moreover, MMA and HCys values were normal in 23% and 49% of cases, respectively, and both metabolite levels were normal in 21% of evaluable cases even though more modest metabolite cutoff levels (ie, more than 2 SD) were used (Table 3). In fact, commonly employed algorithms would have excluded 57% of these patients from metabolite testing and 63% from Cbl therapy (Figure 1). Furthermore, the low incidence of increased MMA levels in responders cannot be explained by decreased production of propionic acid by gut flora because concurrent antibiotic use occurred in only one patient in this group ("Results" and Lindenbaum et al<sup>11</sup>). Finally, high MMA and HCys values were as frequent in the 25 patients who did not respond to Cbl therapy as they were in the 37

**Table 5. Possible mechanisms of responses to Cbl therapy**

Category and mechanisms	Laboratory tests	
	Cbl	MMA/Hcys
Vitamin deficient: decreased dietary intake and decreased absorption	Low	High
Vitamin dependent: impaired transport, impaired coenzyme formation, abnormal apoenzymes, and Cbl inhibitors	Normal	High
Vitamin responsive: pharmacologic effects on Cbl-related processes and Cbl-unrelated processes	Normal	Normal

responders (Table 4). Moreover, all but 1 of the 15 nonresponders tested with MMA values above 376 nmol/L had a marked decrease in the level of this metabolite after Cbl therapy, suggesting a dissociation of metabolic and clinical responses to treatment. Thus, low Cbl and increased metabolite levels are neither sensitive markers of Cbl-responsive disorders nor are they predictive of a subsequent clinical response to Cbl therapy.

While these inconsistencies in serum Cbl and metabolite levels as indicators of clinical Cbl deficiency may reflect either biologic variability or inaccuracies associated with large-scale commercial testing, alternate mechanisms of the response to Cbl therapy may also explain the findings in this report, particularly when it is recognized that high pharmacologic doses of Cbl were used in these therapeutic trials (Table 5). First, classic *vitamin deficiency* should result in both low serum Cbl levels and elevated metabolite values. Second, *vitamin-dependent* disorders associated with inherited or acquired abnormalities of Cbl metabolism should result in elevated metabolite levels but normal serum Cbl values.<sup>39-42</sup> Finally, it is speculated that in *vitamin-responsive* disorders, normal Cbl and metabolite levels would be expected if the high therapeutic doses of Cbl currently used in clinical practice have *pharmacologic*

effects on Cbl-related processes or on cellular functions completely unrelated to the known physiologic effects of Cbl. In this regard, “functional” deficiency of Cbl has recently been suggested in the pathogenesis of both Alzheimer disease and AIDS myelopathy.<sup>43,44</sup> Moreover, pharmacologic doses of methylcobalamin can improve measures of both cardiac autonomic dysfunction and peripheral neuropathy in diabetic subjects,<sup>45-47</sup> and high doses of methylcobalamin also accelerate nerve regeneration in rats with acrylamide neuropathy.<sup>48</sup> The observation that methylcobalamin can serve as a methyl donor in vitro in the DNA methylase reaction provides one possible mechanism for a pharmacologic effect of Cbl therapy.<sup>49</sup> Analogously, pharmacologic doses of B<sub>6</sub> vitamers have been shown to alter enzymes of vitamin B<sub>6</sub> metabolism, B<sub>6</sub>-dependent apoenzymes, and unrelated enzyme proteins both in vitro and in vivo.<sup>50-55</sup>

It is concluded that (1) short-term intraindividual variations in Cbl, MMA, and Hcys values can affect the recognition of Cbl deficiency; (2) Cbl levels well within the reference range are common in patients with clinical disorders responsive to Cbl therapy; (3) metabolites are frequently normal in patients with hematologic or neurologic abnormalities responsive to pharmacologic doses of Cbl; and (4) the presence of elevated metabolite levels are not predictive of a clinical response to Cbl therapy. Thus, therapeutic trials of Cbl are warranted when clinical findings consistent with Cbl deficiency are present, and further studies of the pharmacologic effects of Cbl coenzymes in the treatment of these disorders are suggested.

## Acknowledgment

The assistance with data analysis and the helpful suggestions of Peter Solomon are gratefully acknowledged.

## Appendix 1: Characteristics of patients with definite clinical responses to Cbl therapy

Case	Age/sex	Causes of Cbl deficiency				Comorbidities			
		Schilling*	IfAb	Gastrin†	Other	DM	EtOH	Smoker	Other
1	28/F	5/10.6	Eq	ND	None	No	No	No	Hypothyroid
2	62/F	5.3/18.1	Neg	210	None	Yes	Yes	No	IgA deficiency
3‡	73/M	24/20	Neg	31	None	No	Yes	Yes	Gout; carotene undetectable
4	36/F	24/26	Neg	66; 101	None	No	No	No	12 wk pregnant§
5	72/F	23/19	Neg	38	None	No	No	No	MGUS; CAD
6	78/M	8/8	Neg	49	None	Yes	No	No	Calcium malab; CRF
7	26/F	27/26	Neg	35	None	No	No	No	None
8	27/F	ND	Neg	29	None	No	No	No	24 wk pregnant
9	78/F	ND	Neg	259; 406	None	No	No	No	Hypothyroid; $\alpha$ -thalassemia
10	70/F	ND	Neg	48	None	No	No	Yes	Psoriasis
11	81/F	ND	Neg	20	None	No	No	No	CRF; MGUS
12	59/F	ND	Pos	24	None	No	No	No	None
13	78/M	ND	Neg	33	None	No	No	No	CAD
14	70/F	ND	Pos	122	Tagamet	Yes	No	No	GERD; CAD
15	68/M	ND	Neg	22	None	Yes	No	No	CAD
16	82/M	ND	Neg	ND	None	No	No	No	Hypothyroid
17	77/F	21/17	Pos	32	None	No	No	No	CAD; spinal stenosis
18	82/M	ND	Neg	26	None	Yes	No	No	CAD
19	79/M	31/26	Pos	23	Duod. divertic	No	No	No	Hypothyroid
20	74/M	ND	ND	ND	None	No	No	No	None
21	71/M	ND	ND	ND	None	No	No	No	MGUS
22	77/F	ND	Neg	38	None	No	No	No	None

### Appendix 1: Characteristics of patients with definite clinical responses to Cbl therapy (continued)

Case	Age/sex	Causes of Cbl deficiency				Comorbidities			
		Schilling*	IfAb	Gastrin†	Other	DM	EtOH	Smoker	Other
23	77/M	ND	Neg	17	None	Yes	No	No	CAD
24	63/F	ND	ND	ND	Cimetidine	Yes	No	No	None
25	46/F	28/21	ND	ND	Vegetarian	No	No	No	None
26	55/F	ND	Neg	34	None	No	No	Yes	Psoriasis
27	62/F	3.2/2.6	ND	ND	None	Yes	No	No	CAD
28	58/F	ND	Pos	ND	None	Yes	No	No	CAD
29	56/F	ND	Neg	32	None	No	No	No	Colloid goiter
30	66/F	ND	Neg	22	None	No	No	No	Hypothyroid
31	39/F	ND	Neg	25	Vegetarian	No	No	No	None
32	53/F	ND	Eq	111;81	Tagamet	Yes	No	No	CRF
33	28/F	ND	Eq	25	None	No	No	No	None
34	48/F	33/36	Neg	18	None	No	No	No	None
35	70/M	ND	Neg	39	None	No	No	No	None
36	68/M	ND	Neg	46	None	No	No	No	2 yr s/p colon cancer
37	77/M	ND	Neg	13	None	No	No	No	CAD; CVA; autonomic dysfunction

Patients 1 to 8 had hematologic responses to Cbl therapy. Patients 9 to 37 had neurologic responses to Cbl therapy. Cbl indicates cobalamin; IfAB, intrinsic factor antibody; EtOH, ethanol abuse; Eq, equivocal; ND, not done; Neg, negative; MGUS, monoclonal gammopathy of undetermined significance; CAD, coronary artery disease; malab, malabsorption; CRF, chronic renal failure; Pos, positive; GERD, gastroesophageal reflux disease; Duod. divertic, duodenal diverticulum; CVA, cerebrovascular accident; DM, diabetes mellitus; and s/p, after.

\*Schilling test values are given as % excretion without IF/% excretion with IF, with normal values being 9% to 33%/8% to 34%

†Gastrin values are pg/mL, with a normal range up to 40 pg/mL.

‡The patient had both hematologic and neurologic responses to Cbl therapy.

§Patient 4 was 12 weeks pregnant but had an MCV of 109 documented 1 year previously. Her MCV fell to 98 after 1 month of Cbl therapy (5 months before delivery). She was taking prenatal multivitamins with iron throughout her pregnancy.

¶Patient 8 was 24 weeks pregnant with a hematocrit (Hct) of .29 and an MCV of 100. Her Hct increased to .35 after 6 weeks of Cbl therapy without a change in MCV, and she delivered 2 weeks later. She was taking prenatal multivitamins with iron throughout her pregnancy.

### Appendix 2: Vitamin-related laboratory tests in patients with definite responses to Cbl therapy

Case	Cbl, pg/mL	sFol, ng/mL/rFol, g/mL	MMA, nmol/L		HCys, μmol/L		BUN, g/dL/Cr, mg/dL	TSH, mIU/L	EtOH
			Before Rx	After Rx	Before Rx	After Rx			
1	137; 235	18.8/611	"< 400"	ND	ND	ND	ND	1.6	No
2	163; 156	17.9/ND	1829	180	40.4	13.9	27/1.0	1.5	Yes
3*	281; 343	6.6/229	419; 363	183	40.4; 60.7	75.8†	11/1.2	2.75	Yes
4	159	ND/288	"< 400"	ND	4.5	ND	5/0.4	1.7	No
5	201; 201	ND/ND	ND	172	ND	ND	19/0.6	0.7	No
6‡	216; 275	5.6/ND	600	ND‡	39.9	ND‡	42/2.1	1.2	No
7	356; 234	> 20/280	444; 389	138	5.9	ND	12/0.7	1.3	No
8	225; 218	ND/ND	549; 497	237	3.0	ND	14/0.7	ND	No
9	281; 343	> 20/ND	546; 426	209	18.5; 15.5	11.4	25/1.3	2.8	No
10	416; 806	13.4/ND	321; 274	199	9.8; 11.0	7.9	32/1.1	1.55	No
11	942	16.3/ND	314	385	16.8	17.8§	26/2.3	ND	No
12	364; 545	> 20/ND	202; 244	113	16.1; 11.8	9.0	11/1.1	0.38	No
13	409	ND/ND	145	ND	8.9	ND	19/1.0	ND	No
14	916	> 20/ND	326; 286	223	16.7; 17.5	14.8	20/1.3	ND	No
15	567; 706	17.1/ND	323; 313	199	12.2; 13.7	11.5	18/1.2	1.16	No
16	279; 263	> 20/ND	257	137	13.2	10.4	16/1.0	5.38	No
17	287; 329	12.7/ND	362; 288	256	17.7; 14.4	8.9	26/0.9	4.6	No
18	423; 420	12.3/ND	397; 328	253	10.7; 8.0	8.8	22/1.4	1.85	No
19	297; 298	14.2/ND	478; 377	255	11.9; 11.4	10.7	17/0.8	4.1	No
20	762	ND/ND	140	ND	9.4	ND	13/1.0	4.08	No
21	517; 565	13.7/ND	164; 157	ND	12.0; 11.4	ND	12/1.2	2.45	No
22	344; 337	12.2/ND	309; 261	171	17.9; 17.2	17.1	17/1.1	2.64	Yes
23	478; 458	> 20/ND	258; 305	166	9.4	ND	16/1.1	1.44	No
24	522	ND/ND	137	ND	8.7	ND	10/0.9	1.31	No
25	174; 253	ND/ND	ND	ND	ND	ND	7/0.5	0.80	No
26	344	14.7/203	375	121	10.4	ND	18/0.7	0.92	No
27	155	ND/346	1928	189	29.3	7.2	11/0.8	ND	No
28	587	7.9/ND	255; 298	179	18.1; 18.4	13.8	23/1.4	ND	No
29	469	> 20/ND	270; 329	202	8.9	7.0	17/0.9	0.72	No

### Appendix 2: Vitamin-related laboratory tests in patients with definite responses to Cbl therapy (continued)

Case	Cbl, pg/mL	sFol, ng/mL/rFol, g/mL	MMA, nmol/L		HCys, μmol/L		BUN, g/dL/Cr, mg/dL	TSH, mIU/L	EtOH
			Before Rx	After Rx	Before Rx	After Rx			
30	724; 537	> 20/ND	265; 288	222	14.6; 11.1	6.2	15/0.8	3.36	No
31	540; 605	ND/ND	312; 349	165	4.8; 7.2	ND	10/0.8	2.28	No
32	286; 357	18.2/ND	590; 487	119	13.6; 18.9	14.0§	58/2.4	1.87	No
33	161	14.3/ND	1006	133	9.8	5.5	9/0.9	1.29	No
34	270; 279	ND/ND	425; 639	132	11.3; 13.1	7.8	10/1.0	2.2	No
35	370	> 20/ND	296	143	9.4	6.5	21/1.1	0.60	No
36	356	11.0/ND	222	ND	10.5	ND	16/1.3	1.06	No
37	1623; 675	> 20/935	341; 520	300	11.4; 17.2	9.3	23/1.4	2.08	No

Normal values not given in the body of text were as follows: sFol, more than 5.4 ng/mL; rFol, 145 ng/mL or more; BUN, 7 to 30 mg/dL; Cr, 0.5 to 1.3 mg/dL; TSH, 0.35 to 5.50 mIU/L.

Cbl indicates cobalamin; sFol, serum folate; rFol, red cell folate; MMA, methylmalonic acid; HCys, homocysteine; BUN, blood urea nitrogen; Cr, serum creatinine; TSH, thyroid stimulating hormone; EtOH; ethanol abuse; before Rx, prior to cobalamin therapy; after Rx, after cobalamin therapy; ND, not done.

\*Patient 3 had both hematologic and neurologic responses to Cbl therapy

†HCys level returned to normal when patient 3 abstained from EtOH.

‡Patient 6 later relapsed off Cbl therapy with an MMA value of 1110 nmol/L and an HCys value of 32.2 μmol/L. Reinstitution of Cbl therapy led to a fall of MMA to 332 nmol/L and HCys to 18.7 μmol/L despite a persistent serum creatinine level of 2.2 mg/dL.

§Persistent high HCys level in these patients (patients 11 and 32) may relate to chronic renal failure (creatinine, 2.3 and 2.4, respectively).

### Appendix 3: Clinical and laboratory findings in all patients evaluated for hematologic or neurologic abnormalities

	Treated patients				Untreated patients
	Definite responders	Possible responders	Nonresponders	Unevaluable for response	
<b>Clinical abnormality, no.</b>	37	33	25	33	127
Hematologic, no. (%)	7 (19)	15 (45)	21 (84)	18 (55)	98 (77)
Neurologic, no. (%)	29 (78)	18 (55)	1 (4)	14 (42)	22 (17)
Both, no. (%)	1 (3)	0	3 (12)	1 (3)	7 (6)
<b>Cobalamin therapy, no.</b>	37	33	25	33	NA
Oral, no. (%)	7 (19)	7 (21)	9 (36)	12 (36)	NA
Intramuscular, no. (%)	30 (81)	26 (79)	16 (64)	21 (64)	NA
<b>Lowest Cbl, no.</b>	37	33	25	33	127
Less than 201 pg/mL, no. (%)	6 (16)	6 (18)	5 (20)	8 (24)	8 (6)
201-300 pg/mL, no. (%)	11 (30)	12 (36)	9 (36)	12 (36)	45 (36)
More than 300 pg/mL, no. (%)	20 (54)	15 (44)	11 (44)	13 (39)	74 (58)
More than 400 pg/mL, no. (%)	15 (41)	9 (26)	7 (28)	8 (24)	52 (41)
<b>Highest MMA, no.</b>	5	31	25	29	112
Less than 251 nmol/L, no. (%)*	8 (23)	14 (45)	3 (12)	9 (31)	98 (88)
251-376 nmol/L, no. (%)	14 (40)	7 (23)	7 (28)	13 (45)	13 (11)†
More than 376 nmol/L, no. (%)	13 (37)	10 (32)	15 (60)	7 (24)	1 (1)‡
<b>Highest HCys, no.</b>	33	27	21	27	101
Less than 12.2 μmol/L, no. (%)	16 (49)	16 (59)	8 (38)	11 (41)	89 (88)
12.2-13.6 μmol/L, no. (%)	2 (6)	4 (15)	4 (19)	2 (7)	4 (4)
More than 13.6 μmol/L, no. (%)	15 (45)	7 (26)	9 (43)	14 (52)	8 (8)

Cbl indicates cobalamin; MMA, methylmalonic acid; HCys, homocysteine; NA, not applicable.

\*Includes patients with MMA values reported as more than 400 nmol/L.

†Repeat values in 2 patients were normal.

‡Repeat value in this patient was normal.

### References

- Lindenbaum J, Heaton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. *N Engl J Med.* 1988;318:1720-1728.
- Heaton EB, Savage DG, Brust CM, Garrett TJ, Lindenbaum J. Neurologic aspects of cobalamin deficiency. *Medicine.* 1991;70:229-241.
- Spivak JL. Masked megaloblastic anemia. *Arch Intern Med.* 1982;142:2111-2114.
- Green R, Kuhl W, Jacobson R, Johnson C, Carmel R, Beutler E. Masking of macrocytosis by α-thalassemia in blacks with pernicious anemia. *N Engl J Med.* 1982;307:1322-1325.
- Carmel R. Pernicious anemia: the expected findings of very low serum cobalamin levels, anemia and macrocytosis are often lacking. *Arch Intern Med.* 1988;148:1712-1714.
- Martin DC, Francis J, Protetch J, Huff FJ. Time dependency of cognitive recovery with cobalamin replacement: report of a pilot study. *J Am Geriatr Soc.* 1992;40:168-172.
- Chanarin I. The response to specific therapy in the megaloblastic anaemias. In: *The Megaloblastic Anaemias.* 2nd ed. Oxford, United Kingdom: Blackwell Scientific Publications; 1979: 287-290.
- Stabler SP, Allen RH, Savage DG, Lindenbaum J. Clinical spectrum and diagnosis of cobalamin deficiency. *Blood.* 1990;76:871-881.
- Matchar DB, McCrory DC, Millington DS, Feussner JR. Performance of the serum cobalamin assay for diagnosis of cobalamin deficiency. *Am J Med Sci.* 1994;308:276-283.
- Moelby L, Rasmussen K, Jensen MK, Pedersen KO. The relationship between clinically confirmed

- cobalamin deficiency and serum methylmalonic acid. *J Intern Med.* 1990;228:373-378.
11. Lindenbaum J, Savage DG, Stabler SP, Allen RH. Diagnosis of cobalamin deficiency, II: relative sensitivities of serum cobalamin, methylmalonic acid and total homocysteine concentrations. *Am J Hematol.* 1990;34:99-107.
  12. Savage DG, Lindenbaum J, Stabler SP, Allen RH. Sensitivity of serum methylmalonic acid and homocysteine determinations for diagnosing cobalamin and folate deficiencies. *Am J Med.* 1994;96:239-246.
  13. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. *Arch Intern Med.* 1999;159:1289-1298.
  14. Nexø E, Hansen M, Rasmussen K, Lindgren A, Grasbeck R. How to diagnose cobalamin deficiency. *Scand J Clin Lab Invest Suppl.* 1994;219:61-76.
  15. Green R. Screening for vitamin B12 deficiency: caveat emptor. *Ann Intern Med.* 1996;124:509-511.
  16. Holleland G, Schneede J, Ueland PM, Lund PK, Refsum H, Sandberg S. Cobalamin deficiency in general practice: assessment of the diagnostic utility and cost-benefit analysis of methylmalonic acid determination in relation to current diagnostic strategies. *Clin Chem.* 1999;45:189-198.
  17. Bolann BJ, Solli JD, Schneede J, et al. Evaluation of indicators of cobalamin deficiency defined as cobalamin-induced reduction in increased serum methylmalonic acid. *Clin Chem.* 2000;46:1744-1750.
  18. Chanarin I, Metz J. Diagnosis of cobalamin deficiency: the old and the new. *Br J Haematol.* 1997;97:695-700.
  19. Klee GG. Cobalamin and folate evaluation: measurement of methylmalonic acid and homocysteine vs vitamin B12 and folate. *Clin Chem.* 2000;46:1277-1283.
  20. Green R, Kinsella LJ. Current concepts in the diagnosis of cobalamin deficiency. *Neurology.* 1995;45:1435-1440.
  21. Zittoun J, Zittoun R. Modern clinical testing strategies in cobalamin and folate deficiency. *Semin Hematol.* 1999;36:35-46.
  22. Carmel R, Brar S, Agrawal A, Penha PD. Failure of assay to identify low cobalamin concentrations [letter]. *Clin Chem.* 2000;46:2017-2018.
  23. Lindenbaum J, Rosenberg IH, Wilson PW, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. *Am J Clin Nutr.* 1994;60:2-11.
  24. Björkegren K, Svardsudd K. Elevated levels of methylmalonic acid and homocysteine in elderly people: a population-based intervention study. *J Intern Med.* 1999;246:317-324.
  25. Karnaze DS, Carmel R. Neurological and evoked potential abnormalities in subtle cobalamin deficiency states, including those without anemia and with normal absorption of free cobalamin. *Arch Neurol.* 1987;147:429-431.
  26. Shinto NK. Serum vitamin B12 concentration in normal human adult serum assayed by *Euglena gracilis*. *Clin Sci.* 1959;18:389-398.
  27. Chanarin I. The absence of vitamin B12. In: *The Megaloblastic Anaemias*. 2nd ed. Oxford, United Kingdom: Blackwell Scientific Publications; 1979:133-141.
  28. Rasmussen K, Møller J, Ostergaard K, Kristensen MO, Jensen J. Methylmalonic acid concentrations in serum of normal subjects: biological variability and the effect of oral L-isoleucine loads before and after intramuscular administration of cobalamin. *Clin Chem.* 1990;36:1295-1299.
  29. Garg UC, Zheng J, Folsom AR, et al. Short-term variability of plasma homocysteine measurement. *Clin Chem.* 1997;43:141-145.
  30. Thirup P, Ekelund S. Day-to-day, postprandial and orthostatic variation of total plasma homocysteine. *Clin Chem.* 1999;45:1280-1283.
  31. Santhosh-Kumar CR, Deutsch JC, Ryder JW, Kolhouse JF. Unpredictable intra-individual variations in serum homocysteine levels on folic acid supplementation. *Eur J Clin Nutr.* 1997;51:188-192.
  32. Clarke R, Woodehouse P, Ulvik A, et al. Variability and determinants of total homocysteine concentrations in plasma in an elderly population. *Clin Chem.* 1998;44:102-107.
  33. Rasmussen K, Møller J, Lyngbak M. Within-person variation of plasma homocysteine and effects of posture and tourniquet application. *Clin Chem.* 1999;45:1850-1855.
  34. Cobbaert C, Arentsen JC, Mulder P, Hoogerbrugge M, Lindemans J. Significance of various parameters derived from biological variability of lipoprotein(a), homocysteine, cysteine, and total antioxidant status. *Clin Chem.* 1997;43:1958-1964.
  35. Pennypacker LC, Allen RH, Kelly JP, et al. High prevalence of cobalamin deficiency in elderly outpatients. *J Am Geriatr Soc.* 1992;40:1197-1204.
  36. Hvas AM, Juul S, Gerdes LU, Nexø E. The marker of cobalamin deficiency, plasma methylmalonic acid, correlates to plasma creatinine. *J Intern Med.* 2000;247:507-512.
  37. Johnson MA, Hawthorne NA, Brackett WR, et al. Hyperhomocysteinemia and vitamin B-12 deficiency in elderly using Title IIIc nutrition services. *Am J Clin Nutr.* 2003;77:211-220.
  38. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Elevated serum methylmalonic acid concentrations are common among elderly Americans. *J Nutr.* 2002;132:2799-2803.
  39. Fowler B. Genetic defects of folate and cobalamin metabolism. *Eur J Pediatr.* 1998;15(suppl 2):S60-S66.
  40. Miller JW, Ramos MI, Garrod MG, Flynn MA, Green R. Transcobalamin II 775G>C and indices of vitamin B12 status in healthy older adults. *Blood.* 2002;100:718-720.
  41. Lievers KJA, Afman LA, Kluijtmans LAJ, et al. Polymorphisms in the transcobalamin gene: association with plasma homocysteine in healthy individuals and vascular disease patients. *Clin Chem.* 2002;48:1383-1389.
  42. Ames BN, Elson-Schwab I, Silver EA. High dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased Km): relevance to genetic disease and polymorphisms. *Am J Clin Nutr.* 2002;75:616-658.
  43. McCaddon A, Regland B, Hudson P, Davies G. Functional vitamin B12 deficiency and Alzheimer disease. *Neurology.* 2002;58:1395-1399.
  44. Di Rocco A, Bottiglieri T, Werner P, et al. Abnormal cobalamin dependent transmethylation in AIDS-associated myelopathy. *Neurology.* 2002;58:730-735.
  45. Yoshioka K, Tanaka K. Effect of methylcobalamin on diabetic autonomic neuropathy as assessed by power spectral analysis of heart rate variation. *Horm Metab Res.* 1995;27:41-42.
  46. Utsunomiya K, Narabayashi I, Tamura K, et al. Effects of aldose reductase inhibitor and vitamin B12 on myocardial uptake of iodine-123 metaiodobenzylguanidine in patients with non-insulin-dependent diabetes mellitus. *Eur J Nucl Med.* 1998;25:1643-1648.
  47. Kuwabara S, Nakazawa R, Azuma N, et al. Intravenous methylcobalamin treatment for uremic and diabetic neuropathy in chronic hemodialysis patients. *Intern Med.* 1999;38:472-475.
  48. Watanabe T, Kaji R, Oka N, Bara W, Kimura J. Ultra-high dose methylcobalamin promotes nerve regeneration in experimental acrylamide neuropathy. *J Neurol Sci.* 1994;122:140-143.
  49. Pfohl-Leschkowicz A, Keith G, Dirheimer G. Effect of cobalamin derivatives on in vitro enzymatic DNA methylation: methylcobalamin can act as a methyl donor. *Biochemistry.* 1991;30:8045-8051.
  50. Solomon LR, Hillman RS. Vitamin B6 metabolism in human red cells, I: variations in human red cells. *Enzyme.* 1978;23:262-273.
  51. Solomon LR, Hillman RS. Regulation of vitamin B6 metabolism in human red cells. *Am J Clin Nutr.* 1979;32:1824-1831.
  52. Solomon LR, Hillman RS. Vitamin B6 metabolism in idiopathic sideroblastic anaemia and related disorders. *Br J Haematol.* 1979;42:239-253.
  53. Crouch JY, Solomon LR. Inhibition of rat liver transaminases by low levels of acetaldehyde and the pharmacologic effects of B6 vitamers. *Biochem Pharmacol.* 1989;38:3431-3437.
  54. Solomon LR, Crouch JY. delta-Aminolevulinic acid dehydratase in rat liver: studies on the effects of ethanol, acetaldehyde and B6 vitamers. *J Lab Clin Med.* 1990;116:228-236.
  55. Solomon LR, Cohen K. Erythrocyte oxygen transport and metabolism and effects of vitamin B6 therapy in type II diabetes mellitus. *Diabetes.* 1989;38:881-886.